INTEGRATED BIOPHARMA INC
integratedbiopharma.comAI Executive Summary
AI-powered analysis of 10-K filing content
Integrated BioPharma experienced a significant sales decline of 19.3% ($10.5 million) in fiscal 2026, with profit margins collapsing from 10.2% to just 1.8%. Customer concentration risk intensified dramatically, with two customers (Life Extension and Herbalife) now representing 90% of consolidated net sales, up from 84% in the prior year, creating severe dependency risk. The company also lost three major customers in its Other Business Lines segment and reported layoffs, indicating broad operational stress.
Red Flags Detected (9)
Extreme customer concentration: 90% of consolidated net sales from just two customers (Life Extension 68%, Herbalife 25%)
Profit margin collapse from 10.2% to 1.8% year-over-year, an 8.4 percentage point decline
Net sales declined 19.3% ($10,481K) year-over-year
6 more red flags detected
Key Takeaways
Company's financial health is highly dependent on maintaining relationships with just two contract manufacturing customers
Near break-even profitability (1.8% margin) leaves little cushion for further sales declines or cost increases
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.